Survival and Prevalence Tables

Table P. 5-Year Relative Survival, 2012-2022, Louisiana

Primary Site[1]	All Race			White				Black		
	Total	Male	Female	Total	Male		Female		Total	Male	Female
All Sites	67.1%	66.8%	67.4%	68.7%	68.2%	↑	69.4%	↑	63.1%	63.8%	62.3%
Oral Cavity and Pharynx	63.7%	63.4%	64.5%	68.5%	68.7%	↑	67.6%	↑	46.3%	44.2%	52.2%
Lip	90.1%	90.4%	84.3%	90.5%	91.5%		82.2%		71.4%	69.5%	0.0%
Tongue	67.1%	66.7%	68.0%	71.2%	70.9%	↑	71.4%	↑	44.4%	43.1%	47.9%
Salivary Gland	72.0%	65.1%	81.2%	70.0%	63.4%		81.2%		75.7%	70.3%	80.8%
Floor of Mouth	46.4%	43.6%	53.7%	49.7%	45.7%	↑	58.6%	↑	35.8%	37.1%	28.4%
Gum and Other Mouth	56.3%	56.8%	55.3%	58.4%	59.4%		56.8%		51.5%	51.9%	50.7%
Nasopharynx	59.7%	58.6%	63.1%	63.6%	61.6%	↑	70.7%		45.4%	46.0%	43.2%
Tonsil	73.6%	73.9%	71.4%	78.3%	78.4%	↑	77.2%	↑	53.0%	54.1%	44.3%
Oropharynx	46.1%	47.7%	40.6%	50.3%	53.5%	↑	39.6%		34.3%	32.4%	42.3%
Hypopharynx	33.9%	31.5%	43.0%	41.0%	39.1%	↑	48.5%		22.7%	21.1%	28.1%
Other Oral Cavity and Pharynx	44.4%	44.8%	41.9%	57.4%	60.5%	↑	40.2%		18.0%	10.4%	38.1%
Digestive System	44.4%	41.6%	48.1%	46.0%	43.4%	↑	49.5%	↑	41.5%	38.1%	45.7%
Esophagus	20.7%	19.1%	26.9%	22.8%	20.6%	↑	32.2%	↑	14.7%	14.1%	16.3%
Stomach	34.9%	31.2%	41.0%	37.2%	33.9%		42.7%		32.7%	27.9%	39.6%
Small Intestine	72.5%	73.4%	71.7%	75.3%	74.7%		76.1%	↑	67.5%	69.1%	66.0%
Colon and Rectum	65.0%	64.2%	65.8%	67.2%	66.5%	↑	67.9%	↑	61.0%	59.8%	62.1%
Colon excluding Rectum	64.9%	65.0%	64.8%	67.7%	67.5%	↑	67.8%	↑	60.0%	60.1%	59.8%
Cecum	64.3%	65.2%	63.4%	66.9%	67.6%		66.2%	↑	59.2%	60.2%	58.3%
Appendix	83.5%	84.1%	82.9%	87.6%	89.3%	↑	86.2%	↑	70.6%	70.7%	70.1%
Ascending Colon	68.0%	65.5%	70.2%	70.7%	67.4%		73.5%		63.8%	63.4%	64.1%
Hepatic Flexure	64.7%	65.1%	64.2%	66.7%	68.3%		64.4%		61.6%	59.8%	63.6%
Transverse Colon	63.3%	60.6%	66.0%	64.4%	63.3%		65.7%		60.6%	55.8%	64.9%
Splenic Flexure	61.0%	65.7%	54.8%	62.0%	64.1%		57.7%		59.2%	65.7%	52.8%
Descending Colon	66.9%	68.6%	64.5%	70.5%	71.7%		67.9%		61.2%	61.8%	60.6%
Sigmoid Colon	67.1%	68.2%	65.7%	69.3%	69.8%	↑	68.6%		62.7%	63.9%	61.4%
Large Intestine, NOS	27.2%	29.1%	24.9%	26.7%	29.8%		22.8%		27.5%	26.9%	27.9%
Rectum and Rectosigmoid Junction	65.2%	62.9%	68.4%	66.2%	64.8%	↑	68.2%		63.3%	59.3%	68.6%
Rectosigmoid Junction	58.0%	56.0%	60.5%	60.7%	60.5%	↑	61.1%		52.8%	48.5%	57.8%
Rectum	67.0%	64.6%	70.5%	67.6%	65.9%		70.2%		65.7%	61.6%	70.9%
Anus, Anal Canal and Anorectum	69.2%	62.7%	73.3%	71.3%	61.1%		76.8%	↑	63.7%	64.9%	61.7%
Liver and Intrahepatic Bile Duct	17.8%	17.2%	19.8%	18.4%	17.9%	↑	20.0%		15.2%	14.4%	18.2%
Liver	19.2%	18.3%	22.6%	20.4%	19.3%	↑	24.5%		15.8%	15.1%	18.9%
Intrahepatic Bile Duct	7.4%	4.9%	10.3%	6.6%	6.0%	↑	7.3%		8.5%	2.5%	16.3%
Gallbladder	19.7%	14.3%	22.2%	18.9%	15.2%		20.6%		18.7%	13.4%	20.8%
Other Biliary	17.1%	16.1%	17.9%	16.8%	15.8%		17.2%		18.0%	16.8%	18.8%
Pancreas	9.9%	9.6%	10.2%	9.8%	9.9%	↑	9.6%		9.7%	8.2%	11.0%
Retroperitoneum	59.8%	54.1%	63.6%	60.3%	53.8%		66.6%		56.0%	34.5%	61.6%
Peritoneum, Omentum and Mesentery	26.7%	10.2%	28.2%	28.1%	13.5%		29.4%		25.2%	0.0%	26.7%
Other Digestive Organs	11.7%	10.9%	12.3%	9.9%	11.9%		7.9%		14.7%	9.0%	16.7%

Respiratory System	25.4%	23.8%	27.5%	26.0%	23.9%		28.4%		23.8%	23.1%	25.0%
Nose, Nasal Cavity and Middle Ear	60.3%	60.8%	59.4%	65.4%	66.8%	↑	63.5%		44.6%	45.5%	41.4%
Larynx	58.9%	59.6%	56.7%	61.5%	62.0%	↑	60.2%	↑	53.4%	54.4%	49.0%
Lung and Bronchus	22.2%	19.0%	26.0%	22.7%	19.1%		26.8%		20.5%	18.5%	23.4%
Pleura	13.5%	0.0%	30.6%	14.4%	0.0%		30.6%		0.0%	0.0%	0.0%
Trachea, Mediastinum and Other Respiratory Organs	38.9%	44.1%	30.5%	42.7%	50.7%		32.4%		31.1%	33.3%	26.7%
Bones and Joints	65.3%	64.3%	66.3%	64.7%	60.3%		69.3%		64.3%	66.2%	60.4%
Soft Tissue including Heart	67.0%	67.9%	65.7%	69.2%	70.4%	↑	67.5%		61.7%	61.5%	61.5%
Skin excluding Basal and Squamous	94.1%	93.0%	95.7%	94.4%	93.3%	↑	96.0%		84.2%	78.1%	88.5%
Melanoma of the Skin	94.6%	93.6%	96.0%	95.0%	94.0%	↑	96.5%	↑	70.3%	63.8%	74.9%
Other Non-Epithelial Skin	89.6%	87.0%	91.5%	87.7%	85.8%		89.1%		92.9%	88.0%	95.1%
Breast	89.9%	79.2%	90.0%	92.8%	80.5%		92.9%	↑	84.1%	74.2%	84.2%
Female Genital System	66.1%	--	66.1%	70.3%	--		70.3%	↑	57.3%	--	57.3%
Cervix Uteri	65.3%	--	65.3%	67.9%	--		67.9%	↑	58.8%	--	58.8%
Corpus and Uterus, NOS	75.8%	--	75.8%	83.1%	--		83.1%	↑	62.3%	--	62.3%
Corpus Uteri	77.7%	--	77.7%	84.6%	--		84.6%	↑	64.7%	--	64.7%
Uterus, NOS	20.0%	--	20.0%	20.9%	--		20.9%		17.5%	--	17.5%
Ovary	46.6%	--	46.6%	48.2%	--		48.2%	↑	41.2%	--	41.2%
Vagina	47.8%	--	47.8%	48.8%	--		48.8%		49.2%	--	49.2%
Vulva	71.7%	--	71.7%	73.8%	--		73.8%		66.8%	--	66.8%
Other Female Genital Organs	40.5%	--	40.5%	43.8%	--		43.8%		30.9%	--	30.9%
Male Genital System	99.8%	99.8%	--	99.9%	99.9%	↑	--		98.7%	98.7%	--
Prostate	99.9%	99.9%	--	99.9%	99.9%	↑	--		99.0%	99.0%	--
Testis	96.3%	96.3%	--	97.2%	97.2%	↑	--		90.8%	90.8%	--
Penis	66.8%	66.8%	--	69.1%	69.1%		--		60.2%	60.2%	--
Other Male Genital Organs	85.5%	85.5%	--	96.9%	96.9%	↑	--		45.2%	45.2%	--
Urinary System	77.3%	77.7%	76.5%	78.8%	79.2%	↑	77.8%	↑	72.2%	71.9%	72.6%
Urinary Bladder	78.2%	79.9%	72.6%	80.1%	81.1%	↑	76.3%	↑	67.9%	72.6%	57.7%
Kidney and Renal Pelvis	77.7%	76.5%	79.5%	78.8%	78.2%	↑	79.7%		75.0%	72.0%	79.1%
Ureter	50.3%	48.2%	51.7%	51.0%	49.2%		52.2%		41.6%	39.6%	40.8%
Other Urinary Organs	46.9%	52.3%	38.0%	48.4%	52.3%		40.5%		41.3%	49.3%	33.8%
Eye and Orbit	79.5%	77.9%	81.3%	79.1%	77.6%		80.8%		81.1%	76.5%	86.7%
Brain and Other Nervous System	31.8%	30.1%	33.9%	29.9%	28.9%		31.1%	↓	35.0%	30.6%	40.5%
Brain	28.8%	27.7%	30.3%	27.2%	26.6%		27.9%		31.5%	28.6%	35.5%
Cranial Nerves Other Nervous System	79.1%	73.9%	84.1%	78.6%	74.2%		82.7%		77.6%	63.6%	85.6%
Endocrine System	97.4%	94.6%	98.3%	98.0%	95.9%		98.7%	↑	95.4%	90.1%	96.6%
Thyroid	98.8%	97.3%	99.1%	99.1%	97.9%		99.4%	↑	97.8%	96.1%	97.9%
Other Endocrine including Thymus	70.8%	68.0%	72.8%	66.4%	63.3%		69.3%		77.2%	74.2%	78.6%
Lymphoma	74.0%	72.1%	76.3%	75.2%	73.8%	↑	76.6%		70.9%	67.2%	74.9%
Hodgkin Lymphoma	86.9%	85.0%	89.1%	86.3%	84.7%		88.2%		87.6%	84.9%	90.7%
Hodgkin - Nodal	87.4%	85.6%	89.5%	86.8%	85.2%		88.7%		88.0%	85.5%	90.7%
Hodgkin - Extranodal	50.9%	41.5%	62.7%	46.4%	26.0%		57.3%		51.5%	51.5%	^
Non-Hodgkin Lymphoma	72.0%	70.1%	74.3%	73.7%	72.4%	↑	75.1%	↑	67.2%	63.0%	71.7%
NHL - Nodal	68.9%	66.3%	72.0%	70.8%	68.6%	↑	73.3%	↑	61.8%	58.2%	65.4%
NHL - Extranodal	78.1%	77.4%	78.6%	79.2%	79.8%	↑	78.4%		76.4%	71.4%	80.8%

Myeloma	59.5%	59.5%	59.6%	58.9%	59.7%		57.6%		60.0%	58.7%	61.2%
Leukemia	66.6%	66.1%	67.2%	68.3%	67.5%	↑	69.3%	↑	60.7%	60.7%	60.6%
Lymphocytic Leukemia	86.2%	84.7%	88.4%	88.1%	86.5%	↑	90.3%	↑	79.4%	78.8%	80.2%
Acute Lymphocytic Leukemia	70.0%	68.8%	71.4%	71.8%	72.1%		71.5%		65.6%	62.5%	69.8%
Chronic Lymphocytic Leukemia	90.7%	88.8%	93.5%	91.8%	89.5%		95.2%	↑	84.2%	84.6%	83.8%
Other Lymphocytic Leukemia	81.4%	80.2%	84.1%	82.4%	81.6%		84.0%		73.3%	69.2%	80.6%
Myeloid and Monocytic Leukemia	42.7%	40.9%	44.8%	41.5%	39.3%		44.1%		43.7%	41.5%	46.0%
Acute Myeloid Leukemia	27.4%	25.5%	29.5%	25.8%	22.5%		29.7%		28.8%	29.8%	27.7%
Acute Monocytic Leukemia	17.3%	20.7%	9.6%	19.0%	26.2%		8.4%		0.0%	0.0%	0.0%
Chronic Myeloid Leukemia	68.4%	66.7%	70.5%	66.2%	65.7%		66.9%	↓	71.9%	64.6%	79.9%
Other Myeloid/Monocytic Leukemia	36.6%	30.8%	42.6%	37.4%	37.1%		37.9%		12.8%	0.0%	51.1%
Other Leukemia	56.3%	57.5%	53.8%	55.7%	57.7%		52.0%		58.8%	56.9%	60.3%
Other Acute Leukemia	30.1%	25.3%	36.4%	30.7%	25.9%		36.9%		25.8%	^	42.4%
Aleukemic, Subleukemic and NOS	67.8%	72.7%	60.5%	66.1%	71.0%		58.3%		72.4%	79.6%	65.1%
Mesothelioma	10.8%	6.6%	20.2%	10.8%	6.6%		20.1%		8.6%	3.0%	20.5%
Kaposi Sarcoma	66.3%	67.1%	56.8%	81.7%	82.8%	↑	74.1%		54.1%	55.7%	^
Miscellaneous	41.7%	39.9%	43.5%	43.9%	43.2%	↑	44.6%	↑	35.5%	30.4%	40.5%

[1]Except for urinary bladder (in situ and invasive), only invasive cases are included.

^The statistic could not be calculated.

↑ or ↓ Within Louisiana, white sex-specific relative survival is significantly ($p < 0.05$) higher or lower than black sex-specific relative survival.

--Not applicable.

Table Q. Louisiana Prevalence Counts by Region, Invasive Cancers Only, January 1, 2023[1,2]

Site/Region	Louisiana	New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
All Sites	212,390	40,096	44,644	31,871	29,560	13,442	13,080	25,089	15,166
Oral Cavity and Pharynx	5,616	961	1,151	887	795	379	363	668	419
Esophagus	742	124	155	113	86	56	60	102	47
Stomach	1,787	412	388	241	237	96	101	200	112
Colon and Rectum	20,467	3,688	4,036	2,811	3,065	1,333	1,440	2,518	1,583
Liver and Intrahepatic Bile Duct	1,625	449	316	281	206	92	52	161	67
Pancreas	1,374	300	280	242	185	63	71	162	73
Larynx	1,982	374	399	287	293	129	115	260	125
Lung and Bronchus	10,006	1,931	1,987	1,514	1,466	627	628	1,123	737
Melanoma of the Skin	10,893	1,676	2,609	1,906	1,209	760	644	1,158	942
Breast	44,121	9,033	9,010	6,689	6,311	2,580	2,358	5,136	3,067
Cervix Uteri	2,604	512	496	330	371	178	174	356	189
Corpus and Uterus, NOS	6,781	1,284	1,338	927	963	423	443	884	521
Ovary	1,867	397	419	304	222	116	109	193	107
Prostate	50,600	9,419	11,630	6,929	7,037	3,124	2,943	5,994	3,523
Testis	1,952	370	414	279	269	144	141	206	130
Urinary Bladder	8,403	1,541	1,682	1,461	1,112	529	557	998	527
Kidney and Renal Pelvis	11,573	2,074	2,413	1,848	1,766	727	701	1,254	800
Brain and Other Nervous System	1,606	303	344	247	215	105	107	170	115
Thyroid	9,962	1,708	1,916	1,532	1,504	630	722	1,185	767
Hodgkin Lymphoma	2,083	409	416	323	285	140	145	233	133
Non-Hodgkin Lymphoma	9,104	1,823	1,831	1,415	1,253	638	549	1,033	562
Myeloma	2,838	600	616	421	305	158	143	372	224
Leukemia	5,860	933	1,142	934	837	414	397	767	437
Acute Lymphocytic Leukemia	867	153	195	142	120	53	49	99	57
Mesothelioma	116	26	30	26	11	9	^	^	^
Kaposi Sarcoma	231	97	51	18	21	11	^	17	9

[1] January 1, 2023, 23-Year Limited Duration Prevalence counts are based on 2023 cancer prevalence proportions from SEER 17 registries. Populations were estimated by averaging 2022 and 2023 populations.

[2]Inclusion methods: For all sites, we count first invasive tumor for each person diagnosed during the previous 23 years (2000-2022). For each specific cancer site, we count first invasive tumor for each site diagnosed during the previous 23 years (2000-2022).

[3] Breast tumor includes both sexes. [4] Urinary bladder category includes urinary bladder tumor in situ. ^Statistic not displayed due to fewer than 6 prevalent cases.

Table R. Louisiana Prevalence Counts by Age Group, Invasive Cancers Only, January 1, 2023[1,2]

Site/Ages	All ages	0-19	20-39	40-49	50-59	60-69	70-79	80-89
All Sites	212,390	3,717	16,756	26,356	55,100	70,558	39,372	10,204
Oral Cavity and Pharynx	5,616	49	319	752	1,787	1,744	832	232
Esophagus	742	^	11	55	180	293	166	42
Stomach	1,787	9	97	184	430	579	386	112
Colon and Rectum	20,467	61	970	2,443	5,992	6,300	3,676	1,184
Liver and Intrahepatic Bile Duct	1,625	49	32	80	385	673	338	73
Pancreas	1,374	8	75	107	290	443	361	93
Larynx	1,982	^	42	212	616	709	334	77
Lung and Bronchus	10,006	9	137	462	1,933	3,909	2,874	882
Melanoma of the Skin	10,893	122	1,597	1,696	2,491	2,675	1,848	664
Breast	44,121	^	2,724	8,035	12,057	12,957	7,304	2,106
Cervix Uteri	2,604	^	963	739	494	304	83	22
Corpus and Uterus, NOS	6,781	^	434	910	2,012	2,320	933	170
Ovary	1,867	59	289	313	491	429	216	70
Prostate	50,600	^	44	1,798	13,065	23,323	10,917	1,454
Testis	1,952	100	1,254	384	171	35	10	^
Urinary Bladder	8,403	10	177	525	1,681	2,873	2,344	857
Kidney and Renal Pelvis	11,573	186	661	1,623	3,094	3,657	2,036	446
Brain and Other Nervous System	1,606	575	415	226	184	138	53	19
Thyroid	9,962	184	2,632	2,185	2,360	1,771	717	121
Hodgkin Lymphoma	2,083	309	1,020	299	234	139	67	15
Non-Hodgkin Lymphoma	9,104	262	947	1,061	2,024	2,566	1,782	542
Myeloma	2,838	^	76	263	623	965	706	209
Leukemia	5,860	878	532	555	1,082	1,428	1,012	378
Acute Lymphocytic Leukemia	867	682	81	24	43	24	11	^
Mesothelioma	116	^	10	13	23	29	26	13
Kaposi Sarcoma	231	^	108	47	28	22	15	11

[1] January 1, 2023, 23-Year Limited Duration Prevalence. Populations were estimated by averaging 2022 and 2023 populations.

[2] Inclusion methods: For all sites, we count first invasive tumor for each person diagnosed during the previous 23 years (2000-2022). For each specific cancer site, we count first invasive tumor for each site diagnosed during the previous 23 years (2000-2022).

[3] Breast tumor includes both sexes.

[4] Urinary bladder category includes urinary bladder tumor in situ.

^Statistic not displayed due to fewer than 6 prevalent cases.

Other Tables

Table S. Percent of Cases[1,2] with Microscopic Confirmation by Primary Site, All Races and Both Sexes Combined, 2019-2023, Louisiana

	Microscopically Confirmed	All Cases	Percent Microscopically Confirmed
All Sites	131,051	138,779	94.4%
Oral Cavity and Pharynx	3,816	3,864	98.8%
Esophagus	1,333	1,362	97.9%
Stomach	2,120	2,154	98.4%
Small Intestine	993	1,007	98.6%
Colon and Rectum	11,976	12,264	97.7%
Colon excluding Rectum	8,261	8,487	97.3%
Rectum and Rectosigmoid Junction	3,715	3,777	98.4%
Liver	1,484	2,734	54.3%
Pancreas	3,790	4,346	87.2%
Larynx	1,322	1,335	99.0%
Lung and Bronchus	16,188	17,911	90.4%
Melanoma of the Skin	5,120	5,133	99.7%
Breast	18,979	19,127	99.2%
Corpus and Uterus, NOS	3,330	3,367	98.9%
Ovary	1,164	1,235	94.3%
Prostate	20,988	21,309	98.5%
Urinary Bladder	5,079	5,147	98.7%
Kidney and Renal Pelvis	6,120	6,776	90.3%
Brain and Other Nervous System	1,305	1,469	88.8%
Thyroid	3,035	3,046	99.6%
Hodgkin Lymphoma	624	629	99.2%
Non-Hodgkin Lymphoma	4,984	5,098	97.8%
Myeloma	2,126	2,492	85.3%
Leukemia	3,730	3,981	93.7%
Mesothelioma	273	283	96.5%
Kaposi Sarcoma	118	121	97.5%

[1]Case counts represent the total combined number of cases for the 5-year period.
[2]Except for urinary bladder (in situ and invasive), only invasive cases are included.